About Us

Our Story

Landos Biopharma is committed to the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Our lead product candidate, BT-11, is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. The Company is evaluating BT-11 in a Phase 2 ulcerative colitis (UC) study and is planning a Phase 2 Crohn’s disease (CD) study to begin in 2020. Our pipeline is composed of innovative compounds targeting two novel pathways identified using computational pathway modeling.

The Landos vision is to ultimately deliver safer, more effective treatments for patients with IBD.

Management Team

Josep Bassaganya-Riera

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More
Raquel Hontecillas

Raquel Hontecillas, Ph.D.

Chief Scientific Officer

Read More
Jyoti Chauhan

Jyoti Chauhan

Executive Director, Global Clinical Operations & Regulatory Compliance

Read More
Andrew Leber

Andrew Leber, Ph.D.

Scientific Director

Read More
Jennifer Collette

Jennifer Collette

Financial Director

Read More
simon lichtiger

Simon Lichtiger, M.D.

Medical Director

Read More

Board of Directors

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More

Chris Garabedian

Xontogeny, Perceptive Advisors

Read More

Konstantin Poukalov

Perceptive Advisors

Read More

Rod Wong, M.D., MBA

RTW Investments

Read More

Clinical Advisory Board

Maria T. Abreu, M.D.

Read More

Jean-Frederic Colombel, M.D.

Read More

Fabio Cominelli, M.D., Ph.D.

Read More

Asher Kornbluth, M.D.

Read More

William J. Sandborn, M.D.

Read More

Francisco Sylvester, M.D.

Read More

Investors